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ABSTRACT
Background: Gene-nutrient interactions affecting hepatic lipase
(HL) activity may contribute to the interindividual variability of the
cardiovascular disease risk associated with dietary fat intake.
Objective: We determined the associations of dietary fat intake with
postheparin HL activity and the possible modifying effect of the HL
480C3T polymorphism on these associations.
Design: Subjects were recruited from participants in the 2000–2001
follow-up examination of the Hoorn Study. HL activity was deter-
mined in postheparin plasma in a sample of 211 men and 218 women
aged 60–87 y. Information about dietary intake of the participants
was obtained with a validated food-frequency questionnaire. Linear
regression was performed, adjusted for age.
Results: Total dietary fat was positively associated with HL activity
(standardized : 0.11; 95% CI: 0.02, 0.21), and this association was
also seen for saturated fat (0.10; 0.01, 0.20) and monounsaturated
fatty acid (0.10; 0.01, 0.19). We observed a significant interaction of
the HL polymorphism with the relation between total fat intake and
HL activity. The association of total fat with HL activity was stronger
in subjects with CT (0.27; 0.11, 0.43) and TT (0.39; 0.22, 1.00)
genotypes than in subjects with the CC genotype (0.06;0.06, 0.18;
P for interaction  0.10). The interaction remained statistically
significant in models that included age, sex, carbohydrate and pro-
tein intakes, and insulin or body mass index.
Conclusions: Higher intakes of total and saturated fat were posi-
tively associated with higher HL activity. In addition, the observed
association of total fat with HL activity was modified by the
HL480C3T polymorphism, after adjustment for age, sex, carbo-
hydrate and protein intakes, and insulin or body mass index. Am
J Clin Nutr 2005;81:911–5.
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INTRODUCTION
Dietary fat intake is an important predictor of serum lipids and
lipoproteins (1–3). Reduction in saturated fat intake is associated
with decreases in plasma LDL-cholesterol and HDL-cholesterol
concentrations. Triacylglycerol and phospholipids in HDL and
LDL particles are hydrolyzed by hepatic lipase (HL), a lipolytic
enzyme, resulting in the formation of smaller and denser particles.
HL activity has been shown to be determined by genetic fac-
tors (4). A common480C3T substitution, also denominated
LIPC514C3T (5), has been described in the promoter region
of the HL gene (6). The T allele is associated with decreased
plasma HL activity (6, 7). Dietary fat has recently been shown to
modify the association between HL480C3T polymorphism
and plasma HDL-cholesterol concentrations in such a way that
the presence of the T allele was associated with higher HDL
cholesterol, only in individuals who usually consume a low-fat
diet. In contrast, the TT genotype was associated with lower HDL
cholesterol in individuals who usually consume a high-fat diet
(8). Information about the effects of dietary fat on HL activity is
limited and contradictory. A high-fat diet (46% of energy) in-
creased HL activity in 43 healthy men compared with a low-fat
diet (24% of energy) (9). However, no differences in HL activity
were observed after dietary fat restriction in 72 healthy women
(10). In an intervention study with low-fat and high-fat diets in
men, an increase in dietary saturated fat was associated with
decreased HL activity (11).
In this cross-sectional observational study of 429 men and
women, we investigated the association of both dietary fat intake
and HL480C3T polymorphism with HL activity. In addition,
we determined whether the HL480C3T polymorphism mod-
ifies the association of dietary fat intake with plasma postheparin
HL activity.
SUBJECTS AND METHODS
Design and population
The Hoorn Study is a population-based cohort study of glu-
cose metabolism and cardiovascular disease risk factors among
the inhabitants of the municipality of Hoorn, Netherlands, which
started in 1989 and consisted of 2484 subjects, as described
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before (12). In 2000–2001, a follow-up was conducted in se-
lected subjects, then aged 60–87 y. We invited all surviving
subjects with type 2 diabetes (n  176) to participate and also
individuals chosen from random samples with normal glucose
metabolism (n705) or impaired glucose metabolism (n193)
on the basis of their glucose metabolism status at the previous
examination in 1996–1998 (13). Of the 1074 individuals invited,
648 (60.3%) participated in the 2000–2001 follow-up examina-
tion. Among the reasons for not participating in the follow-up
examinations were lack of interest (30%), comorbidity (23%),
advanced age (7%), unwillingness to travel (6%), participation
considered too time consuming (6%), and miscellaneous reasons
(15%). Thirteen percent were complete nonresponders. For the
present study, cross-sectional data of this 2000–2001 follow-up
examination were analyzed. A sample of 585 participants was
invited for the postheparin test, of which 566 participated. The
Ethical Review Committee of the VU University Medical Center
approved the study. Informed consent was obtained from all
participants.
Postheparin plasma HL activity
HL activity was measured by using an immunochemical
method as described previously in plasma collected 20 min after
contralateral intravenous administration of 50 IU heparin/kg
body weight (Leo Pharmaceutical Products, Weesp, Nether-
lands). One hundred seven samples (19%) were excluded from
the analysis because of low activities for lipoprotein lipase (LPL)
and HL in postheparin plasma. The cutoffs for low lipase activ-
ities were selected on the basis of visual inspection of a scatter-
plot. Activities were considered low if both LPL activity
was50 U/L and HL activity was72 U/L. Inclusion of other
subjects with incomplete heparin injections did not change the
results (data not shown). Most excluded samples were among
subjects with impaired glucose metabolism and type 2 diabetes.
However, no statistically significant differences were observed
between individuals who were excluded and the rest of the sub-
jects with respect to lipoproteins, body mass index (BMI), and
dietary fat intake (data not shown). Furthermore, HL activity
showed the known associations with age, sex, HDL-cholesterol
concentration, and triacylglycerol concentration (4, 14). The
postheparin test was repeated in a sample of subjects with nor-
mal and impaired glucose metabolism and diabetes with both
low LPL and HL activities (n  10). Normal LPL and HL ac-
tivities were measured in these subjects, indicating that insuffi-
cient heparin delivery was the cause of the low activities.
Genotyping HL polymorphism
DNA was extracted from blood. We used the polymerase
chain reaction method as described by Berk-Planken et al (15) to
assess the presence of the CT variance in the HL gene pro-
moter.
Glycemic control and lipids
All participants underwent a 75-g oral-glucose-tolerance test,
except for participants with capillary fasting whole blood glu-
cose concentrations8 mmol/L or participants with a previous
diagnosis of diabetes who were treated with oral glucose-
lowering medication or insulin. Fasting glucose and 2-h postload
glucose were measured in plasma with the hexokinase method
(Roche Diagnostics GmbH, Mannheim, Germany). Glycated he-
moglobin was analyzed by HPLC (reference range: 4.3–6.1%).
Fasting plasma glucose, 2-h postload plasma glucose, total-
cholesterol, HDL-cholesterol, and triacylglycerol concentra-
tions were measured by enzymatic methods (Roche, Mannheim,
Germany). LDL cholesterol was directly determined by the
N-geneous assay (Genzyme, Cambridge, MA). Insulin was de-
termined by using a two-site immunoradiometric test. Paired
monoclonal antibodies were used (Medgenix, Diagnostics, Fleu-
rus, Belgium).
Dietary intake
Information about the dietary intake of the participants was
obtained by a validated food-frequency questionnaire (16, 17),
which was linked to an extended version of the computerized
Dutch Food Composition Table 1996 (18). Intake of macronu-
trients was expressed as the percentage of energy as fat [fat (in
kJ)/total energy (in kJ) 100].
Statistical analysis
Three glucose metabolism categories (normal, impaired glu-
cose metabolism, and diabetes) were defined according to the
World Health Organization criteria (19). We excluded people
with missing data on primary variables of interest (glucose me-
tabolism, n 7; HL activity, n 107; HL480C3T polymor-
phism, n  17; and dietary intake, n  6). Thus, the study
population consisted of 429 individuals, 211 men and 218
women. Characteristics of the study population are presented by
polymorphism category. To depict the independent associations
of dietary fat with HL activity, the population was divided into 9
groups by creating a 3 3 table according to tertiles of fat intake
and HL polymorphism groups. To investigate the association of
dietary fat intake (percentage of energy) to the HL activity, linear
regression analysis was performed. HL activity was modeled as
the dependent variable and dietary fat intake as independent
variable. The coefficients for the individual types of fat were
obtained by putting each fat in an individual model. All regres-
sion models were adjusted 1) for age; additionally 2) for sex,
consumption of carbohydrates, and consumption of proteins; and
3) for insulin concentration and glucose metabolism status or
BMI. Stratified analyses were performed to evaluate possible
effect modification by polymorphism. If we observed a linear
trend in the standardized a¯ coefficients, we tested for interactions
of HL polymorphism by calculating the respective interaction
terms. With an F test we checked whether these product terms
significantly improved the model. All associations of the regres-
sion analyses are reported as standardized coefficients. A stan-
dardized  of 0.1 indicates that, if the independent variable
increases 1 SD, the dependent variable (HL activity) decreases
0.1 SD. P values 0.05 were considered statistically significant,
except for interaction analyses, in where we used P  0.10.
Statistical analyses were performed with SPSS for WINDOWS
version 10.1 (SPSS Inc, Chicago).
RESULTS
HL activity was significantly lower in carriers of the TT ge-
notype than in subjects with the CC or CT genotype (P for
trend  0.001; Table 1). Furthermore, the carriers of the TT
genotype had a more favorable lipid profile, ie, with higher HDL
cholesterol (P for trend  0.03). The SD for fasting glucose in
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the TT group is large, because there was one outlier with a fast-
ing glucose concentration of 18.5 mmol/L. Nevertheless, we did
not exclude this subject from the analysis; the extreme value was
a true observation because the person was a diabetic subject. No
significant differences in dietary fat intake across HL polymor-
phisms were detected. Genotype frequencies did not deviate
from the Hardy-Weinberg equilibrium.
The HL480C3T polymorphism was the strongest predic-
tor of HL activity [ (95% CI): 28 (54, 4) for the CT and
138 (210;66) for the TT genotypes compared with the CC
genotype]. Intakes of total fat, saturated fat, and monounsatu-
rated fat were positively associated with HL activity, whereas
intake of polyunsaturated fatty acid was not related to HL activity
(Table 2). A test for interaction between total fat and HL poly-
morphism was significant (P  0.10), indicating that the asso-
ciation of total dietary fat intake with HL activity differs across
categories of HL480C3T polymorphism.
In Table 3, stratified multivariate analyses of total fat intake
and HL activity are shown. After adjustment for carbohydrate
intake, protein intake, and insulin concentration (model 2), total
TABLE 1
Baseline characteristics of the population according to hepatic lipase480C3T polymorphism1
HL polymorphism
P for trend
CC
(n 275)
CT
(n 142)
TT
(n 12)
Age (y) 70 62 69 6 71 9 0.95
Sex (% male) 50 47 50 0.64
Hepatic lipase (U/L) 385 132 357 134 242 53 0.001
Fasting glucose (mmol/L) 6.09 1.32 6.14 1.20 7.08 3.64 0.80
Postload glucose (mmol/L) 6.93 2.27 7.08 2.77 6.54 1.29 0.73
Insulin (pmol/L) 53 (39–75)3 57 (39–84) 42 (32–80) 0.75
Total cholesterol (mmol/L) 5.7 1.1 5.8 0.9 5.7 1.0 0.28
HDL cholesterol (mmol/L) 1.40 0.40 1.48 0.44 1.55 0.35 0.03
LDL cholesterol (mmol/L) 3.7 0.9 3.7 0.9 3.7 0.8 0.77
Triacylglycerol (mmol/L) 1.3 (1.0–1.7) 1.3 (0.9–1.7) 1.1 (0.9–1.4) 0.87
Systolic blood pressure (mm Hg) 142 20 141 22 139 19 0.52
Diastolic blood pressure (mm Hg) 82 11 82 11 82 14 0.69
Antihypertensive drugs (%) 67 64 83 0.07
Lipid lowering (%) 16 13 0 0.21
BMI (kg/m2) 26.7 3.4 27.3 4.2 26.3 3.1 0.15
Energy intake (kJ/d) 8296 3584 8367 2197 7364 1959 0.89
Total fat intake (% of energy) 34.5 5.9 34.4 5.8 37.8 4.3 0.20
Saturated fat intake (% of energy) 14.7 3.2 14.4 2.6 17.2 3.3 0.28
MUFA intake (% of energy) 13.1 2.6 13.0 2.8 14.0 2.2 0.21
PUFA intake (% of energy) 6.4 2.2 6.6 2.4 6.1 1.9 0.71
Carbohydrate (% of energy) 45.7 7.1 45.8 6.2 43.4 5.9 0.69
Protein (% of energy) 15.2 2.5 15.2 2.3 15.4 2.4 0.69
1 MUFA, monounsaturated fat; PUFA, polyunsaturated fat.
2 x  SD (all such values).
3 Median; interquartile range in parentheses (all such values).
TABLE 2
Standardized  coefficients (95% CIs) for age-adjusted associations of dietary fat intake with hepatic lipase (HL) activity by HL480C3T
polymorphism: univariate regression analyses1
HL polymorphism
CC
(n 275)
CT
(n 142)
TT
(n 12)
Overall
(n 429)
Total fat 0.06 (0.06, 0.18) 0.27 (0.11, 0.43)2 0.39 (0.22, 1.00) 0.113 (0.02, 0.21)4
Saturated fat 0.11 (0.01, 0.23) 0.17 (0.01, 0.33) 0.24 (0.20, 0.41) 0.10 (0.01, 0.20)
MUFA 0.04 (0.07, 0.16) 0.23 (0.07, 0.39) 0.43 (0.15, 1.01) 0.10 (0.01, 0.19)
PUFA 0.05 (0.17, 0.07) 0.20 (0.04, 0.36) 0.03 (0.71, 0.66) 0.04 (0.06, 0.13)
1 MUFA, monounsaturated fat; PUFA, polyunsaturated fat.
2 Significant association of total fat intake with HL activity in the model, P 0.05.
3 A standardized  of 0.11 indicates that if the independent variable (total fat intake) increases by 1 SD, the dependent variable (HL activity) will increase
by 0.11 SD. This corresponds with a slope () of 2.61, which indicates that if the total fat intake increases by 1% of energy, HL activity will increase by a mean
of 2.61 U/L in the entire population. The reason that we used standardized coefficients was because of the possibility of making comparisons between different
models, ie, the association between different types of fat and HL activity.
4 Simultaneous test for both interaction terms, P 0.09.
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fat intake tended to be positively associated with HL activity in
subjects with CT and TT genotypes, but not in subjects with the
CC genotype; however, none of these associations was statisti-
cally significant. These associations were seen after additional
adjustment for insulin and not after adjustment for carbohydrate
and protein intake only (model 1). After adjustment for glucose
metabolism status or BMI (models 3 and 4), a positive associa-
tion was observed between total fat intake and HL activity in the
same direction as in models 1 and 2. These associations were
statistically significant for the CT genotype in model 3. The
overall F test for interactions between total fat and HL polymor-
phisms reached statistical significance after adjustment for car-
bohydrate and protein intakes, insulin (P 0.07; model 2), and
BMI (P 0.04; model 4).
DISCUSSION
In this population-based study, we describe the effects of di-
etary fat intake on HL activity. We found that the T allele was
associated with lower HL activity, and this relation was inde-
pendent of the amount and type of fat consumed. In addition, we
found a stronger association of total dietary fat intake with HL
activity in subjects with CT and TT genotypes than in subjects
with the CC genotype, after adjustment for age, sex, carbohy-
drate and protein intakes, and insulin or BMI.
In the Framingham study, the T allele was associated with
significantly greater HDL-cholesterol concentrations only in
subjects consuming30% of energy from fat (8). The observed
gene-nutrient interaction with HDL cholesterol was in the same
direction as our findings with HL activity. In line with our results,
higher intake of saturated fat was associated with higher HL
activity in 43 men in a study of Dreon et al (11). It has been
described that HL activity is quite variable, indicating that other
factors affect HL activity. HL activity is higher in men, in smok-
ers, and in those with diabetes, and it is positively associated with
intraabdominal fat and BMI (4, 14). Thus, HL activity is asso-
ciated with several components of the insulin resistance syn-
drome (15, 20–23).
The design of our study did not allow us to investigate the
mechanism by which dietary fat possibly interacts with the
480C3T polymorphism. Investigations in rats have shown
that the dietary lipid profile is an important predictor of tissue
phospholipid composition (24), which may, in turn, influence
insulin sensitivity by altering membrane fluidity and insulin sig-
naling (25, 26). One possibility is a direct effect of fatty acids on
HL expression. It has been shown that fatty acids enhance HL
activity secreted from HepG2 cells (27). Therefore, HL activity
could be modulated by a change in the supply of fatty acids to the
liver either from the diet or from the omental fat stores. Addi-
tionally, it has been hypothesized that the underlying mechanism
could be insulin resistance of the T allele at the level of gene
expression (H Jansen, unpublished observations, 2004). Previ-
ous studies have reported that insulin up-regulates the activity of
HL by insulin-responsive elements in the HL promoter, suggest-
ing that variants in this promoter, as examined in this study, may
affect the ability of insulin to stimulate HL activity (28). Jansen
et al (6) have reported an association between variants of the HL
promoter and insulin resistance. However, in our study, adjust-
ment for insulin concentration did not change the observed as-
sociation between total fat intake and HL activity in any of the
genotypes.
Some limitations of our study should be noted. First, the num-
ber of subjects in the groups with the TT genotype was small
(n  12), thus reducing the statistical power for conclusions
about this group. However, this study is the first to measure HL
activity in such a large population and to investigate relations
between HL activity and HL polymorphisms. Furthermore, we
observed different associations in the CT genotype group. Sec-
ond, our findings were obtained in the elderly. Therefore, we may
have underestimated the association of dietary fat intake with HL
activity because of selective morbidity and mortality of individ-
uals with unhealthy lifestyle and food consumption and conse-
quently unfavorable lipase activity or related lipoproteins.
In summary, total dietary fat and saturated fat were positively
associated with HL activity. In addition, we observed a gene-
nutrient interaction (in a model that included BMI), such that the
association of the amount of total fat consumed with HL activity
depended on the HL 480C3T polymorphism. Gene-nutrient
interactions may help to explain the different outcomes of plasma
lipoprotein in response to dietary fat and the conflicting results
about HL activity and cardiovascular disease risk.
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for carrying out the postheparin lipase test.
GB performed the data analyses and wrote the drafts and final paper. JMD,
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TABLE 3
Standardized  coefficients (95% CI) for associations of dietary total fat intake with hepatic lipase (HL) activity by HL480C3T polymorphism:
multivariate regression analysis
Model1
HL polymorphism
P for interaction2
CC
(n 275)
CT
(n 142)
TT
(n 12)
1 0.02 (0.17, 0.12) 0.19 (0.02, 0.40) 0.35 (1.24, 1.93) 0.13
2 0.04 (0.19, 0.10) 0.20 (0.002, 0.41) 0.25 (1.02, 1.52) 0.07
3 0.03 (0.17, 0.11) 0.22 (0.02, 0.42) 0.50 (0.97, 1.97) 0.11
4 0.05 (0.19, 0.08) 0.23 (0.03, 0.43)3 0.29 (0.81, 1.38) 0.04
1 Model 1, total fat intake adjusted for age, sex, and carbohydrate and protein intakes; model 2, model 1 insulin; model 3, model 1 glucose metabolism
status; model 4, model 1 BMI.
2 Interaction between total fat intake and HL polymorphism.
3 Significant association of total fat intake with HL activity in the model, P 0.05.
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